Three Projects of MicroPort Selected in the 2011 Science & Technology Innovation Plan by STCSM

[2011-12-19]

MicroPort submitted the "Research of the Technical Standard for Minimally Invasive Intervention of Biological Valves" and "Shanghai Engineering Technology Research Center for Minimally Invasive Intervention and Implantable Devices" projects in December 2011 and three have been selected for the 2011 Science and Technology Innovation Plan, by the Science and Technology Commission of Shanghai Municipal (STCSM), for the Technological Standard Subject(category) and the Shanghai Engineering R&D Center Construction Subject (category), respectively. The Technological Standard Subject aims to establish a set of industrial, national and international standards with independent intellectual property rights, achieved through studies of standard systems, leading products and key accessories technological criterion. The Shanghai Engineering R&D Center Construction Subject primarily focuses on minimally invasive medical devices and anti-cancer drugs in the biomedical field. Significantly, it aims to strengthen Engineering-orientated R&D abilities and achieve transformation in accordance with the Shanghai Science and Technology Innovation Plan strategic key and common technology problems for emerging industries.
 
The "Clinical Evaluation and Technology Research for Cardiovascular Interventional Devices", jointly applied by MicroPort, Shanghai Ruijin Hospital, Changhai Hospital, University of Shanghai for Science and Technology, and Gateway Medical Innovation Center, has also selected in the Science and Technology Innovation Plan as an industry-institution-hospital joint cooperation project. It is the first time STCSM has sought to initiate further collaboration and cooperation between our industry, academic institutions, and hospitals in the biomedical field.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2019 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs MicroPort Scientific Corporation
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6957
Email: spokesperson@microport.com